Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Dave S. Solis"'
Autor:
Cheryl Janson, Martin Weisel, Barry Goggin, Liang Weiling, Adrian J. Fretland, Robert Francis Kester, Christine Lukacs, Edmund Lee, Jennifer Lo, J. Heather Hogg, Xiaochun Han, Kyoungja Hong, Stacy Remiszewski, Shirley Li, Ann Polonskaia, John Anthony Moliterni, Kang Le, Lin Gao, Nam T. Le, Christophe Michoud, A. Schutt, Shahid Tannu, Andrew F. Donnell, Shaoqing Chen, Louis J. Lombardo, Steven Gregory Mischke, Mark T. Dvorozniak, Yan Lou, Christine Tardell, Kenneth Carey Rupert, Doug Aguilar, Dave S. Solis
Publikováno v:
Journal of medicinal chemistry. 56(20)
The IAPs are key regulators of the apoptotic pathways and are commonly overexpressed in many cancer cells. IAPs contain one to three BIR domains that are crucial for their inhibitory function. The pro-survival properties of XIAP come from binding of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54996c22c1d8fb8749b427ec42349aeb
https://pubmed.ncbi.nlm.nih.gov/24093940
https://pubmed.ncbi.nlm.nih.gov/24093940
Autor:
Kang Le, Christophe Michoud, Robert T. Taylor, Christine Lukacs, Andrew D. Schutt, Lin Gao, Anthony Specian, Kenneth Carey Rupert, Stacy Remiszewski, Ann Polonskaia, Douglas Aguilar, Barry Goggin, John Anthony Moliterni, J. Heather Hogg, Liang Weiling, Xiaochun Han, Cheryl Janson, Louis J. Lombardo, Martin Weisel, Adrian J. Fretland, Steven Gregory Mischke, Norman Kong, Shirley Li, Robert Francis Kester, Andrew F. Donnell, Kyoungja Hong, Dave S. Solis, Karl Frank, Yan Lou
Publikováno v:
Journal of medicinal chemistry. 56(20)
XIAP is a key regulator of apoptosis, and its overexpression in cancer cells may contribute to their survival. The antiapoptotic function of XIAP derives from its BIR domains, which bind to and inhibit pro-apoptotic caspases. Most known IAP inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e48ef3b240f2787ad2fc864469665b6
https://pubmed.ncbi.nlm.nih.gov/24083782
https://pubmed.ncbi.nlm.nih.gov/24083782
Publikováno v:
Blood. 108(8)
HLA-DR is under investigation as a target for monoclonal antibody (mAb) therapy of malignancies. Here we describe a humanized IgG4 form of the anti-HLA-DR mAb L243, hL243γ4P (IMMU-114), generated to provide an agent with selectivity toward neoplasti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0bb9d7e18881fd327883f371d498bac
https://pubmed.ncbi.nlm.nih.gov/16778139
https://pubmed.ncbi.nlm.nih.gov/16778139